Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy
Figure 2
(a) CD4+/CD38+/DR+, (b) CD8+/CD38+/DR+, percentage of apoptotic T cells, (c) CD4+/CD95+, (d) CD8+/CD95+. Line represents median; rank-sum test; BL: baseline.
(a)
(b)
(c)
(d)
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.